<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1816">
  <stage>Registered</stage>
  <submitdate>7/02/2008</submitdate>
  <approvaldate>7/02/2008</approvaldate>
  <nctid>NCT00611702</nctid>
  <trial_identification>
    <studytitle>Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)</studytitle>
    <scientifictitle>Genomics of Chronic Renal Allograft Rejection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DAIT GTCRP-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Transplantation</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Kidney biopsy

Treatment: surgery: Kidney biopsy
Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Correlation of chronic rejection with patterns and intensity of recipient alloreactivity</outcome>
      <timepoint>Throughout study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Correlation of chronic rejection with recipient gene expression profiles</outcome>
      <timepoint>Throughout study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Correlation of chronic rejection with polymorphic variants of specific susceptibility genes in donor and recipient</outcome>
      <timepoint>Throughout study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of the development of donor specific antibodies after transplant and/or the presence of C4d staining with patterns and intensity of recipient alloreactivity</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of the development of donor specific antibodies after transplant and/or the presence of C4d staining with recipient gene expression profiles</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of the development of donor-specific antibodies after transplant and/or the presence of C4d staining of peritubular basement membranes on renal biopsy with polymorphic variants of specific susceptibility genes in donor and recipient</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of the development of donor-specific antibodies after transplant and/or the presence of C4d staining of peritubular basement membranes on renal biopsy with chronic rejection</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of the development of donor-specific antibodies after transplant and/or the presence of C4d staining of peritubular basement membranes on renal biopsy allograft dysfunction as defined by the protocol</outcome>
      <timepoint>Throughout study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Kidney transplant candidates from living or deceased donors

          -  Male or female, ages 18-75 years

          -  Subject must be able to understand and provide written informed consent

          -  Living Donors - Recipient also consents to participate in the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Presence of Donor Specific Antibodies in living donor recipients prior to
             transplantation OR positive cross match according to site-specific technique in
             cadaveric donor recipients

          -  Recipients of multiple organ transplants, with the exception of kidney/pancreas
             transplants.

          -  Inability or unwillingness to comply with the study protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>588</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Westmead Hospital - Sydney</hospital>
    <postcode>2145 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institute of Allergy and Infectious Diseases (NIAID)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Doctors have had success preventing certain types of kidney transplant rejection by
      suppressing the immune system. However, an individual's genetic make-up and the strength of
      an immune response to a transplant may also determine whether a transplanted organ is
      rejected. The purpose of this study is to look at the genetic profile and immune response of
      people who have had kidney transplants and to correlate the findings with kidney transplant
      rejection episodes. Donor genetic profiles will also be studied and correlated with the
      recipient's information.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00611702</trialwebsite>
    <publication>Vitalone MJ, O'Connell PJ, Wavamunno M, Fung CL, Chapman JR, Nankivell BJ. Transcriptome changes of chronic tubulointerstitial damage in early kidney transplantation. Transplantation. 2010 Mar 15;89(5):537-47. doi: 10.1097/TP.0b013e3181ca7389.
Vitalone MJ, O'Connell PJ, Jimenez-Vera E, Yuksel A, Wavamunno M, Fung CL, Chapman JR, Nankivell BJ. Epithelial-to-mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol. 2008 Aug;19(8):1571-83. doi: 10.1681/ASN.2007050580. Epub 2008 May 14.
Dinavahi R, George A, Tretin A, Akalin E, Ames S, Bromberg JS, Deboccardo G, Dipaola N, Lerner SM, Mehrotra A, Murphy BT, Nadasdy T, Paz-Artal E, Salomon DR, Schröppel B, Sehgal V, Sachidanandam R, Heeger PS. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol. 2011 Jun;22(6):1168-78. doi: 10.1681/ASN.2010111183. Epub 2011 May 12.
Krüger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, Lin M, Walsh L, Vella J, Fischereder M, Krämer BK, Colvin RB, Heeger PS, Murphy BT, Schröppel B. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3390-5. doi: 10.1073/pnas.0810169106. Epub 2009 Feb 13.
Wavamunno MD, O'Connell PJ, Vitalone M, Fung CL, Allen RD, Chapman JR, Nankivell BJ. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant. 2007 Dec;7(12):2757-68. Epub 2007 Oct 6.
Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, Ames S, Lerner S, Ebcioglu Z, Nair V, Dinavahi R, Sehgal V, Heeger P, Schroppel B, Murphy B. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant. 2010 Sep;10(9):2132-2141. doi: 10.1111/j.1600-6143.2010.03210.x. Erratum in: Am J Transplant. 2010 Dec;10(12):2728.
Farris AB, Adams CD, Brousaides N, Della Pelle PA, Collins AB, Moradi E, Smith RN, Grimm PC, Colvin RB. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol. 2011 Jan;22(1):176-86. doi: 10.1681/ASN.2009091005. Epub 2010 Nov 29.
Schröppel B, Krüger B, Walsh L, Yeung M, Harris S, Garrison K, Himmelfarb J, Lerner SM, Bromberg JS, Zhang PL, Bonventre JV, Wang Z, Farris AB, Colvin RB, Murphy BT, Vella JP. Tubular expression of KIM-1 does not predict delayed function after transplantation. J Am Soc Nephrol. 2010 Mar;21(3):536-42. doi: 10.1681/ASN.2009040390. Epub 2009 Dec 17.
Luan Y, Mosheir E, Menon MC, Wilson D, Woytovich C, Ochando J, Murphy B. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion. Am J Transplant. 2013 Dec;13(12):3123-31. doi: 10.1111/ajt.12461. Epub 2013 Sep 18.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barbara T. Murphy, MD</name>
      <address>Division of Nephrology, Mt. Sinai School of Medicine</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>